Manatuck Hill Partners, LLC Exelixis, Inc. Transaction History

Manatuck Hill Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $1.72 Million - $2.45 Million	110,000 New	110,000 $1.73 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $633,600 - $875,200	-40,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $652,000 - $845,600	40,000 New	40,000 $846,000
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $725,180 - $1.03 Million	-40,400 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $829,412 - $1.02 Million	40,400 New	40,400 $913,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Manatuck Hill Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Manatuck Hill Partners, LLC with notifications on news.